Program
TXN10128
A development code.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Txinno Bioscience.
Furthest: phase 2, since Oct 26, 20262 company-led studies, 2 open or runningNext primary completion: Sep 30, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Txinno Bioscience | 22 open or running | phase 2since Oct 26, 2026 | Jul 20, 2023 | Sep 30, 2028phase 2 · NCT07933055 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 20, 2023First study: phase 1 study in Locally Advanced (Unresectable) or Metastatic Solid TumorsFirst studyNCT05978492 · 96 planned · Korea, Republic of
- Oct 26, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungPhase 2 reachedNCT07933055 · 104 planned · South Korea
Ahead
- Sep 30, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07933055
TargetBeta
ENPP1 →read by rule
“A Multicenter, Open-label, Phase 1 Dose Escalation and Expansion Study of TXN10128, an Inhibitor of ENPP1 as Monotherapy and Combination Therapy With Irinotecan or Paclitaxel in Locally Advanced or Metastatic Solid Tumors”study text, by rule · the study
Other programs on ENPP1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ENPP1 Inhibitor RBS2418rule | riboscience-llc | phase 2 | 3 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07933055Carcinoma, Non-Small-Cell Lung · South Korea | 2 | Recruiting | Sep 30, 2028 | 104 |
| NCT05978492Locally Advanced (Unresectable) or Metastatic Solid Tumors · Korea, Republic of | 1 | Recruiting | Dec 31, 2025 | 96 |
How it is read
Names in the registry
- “TXN10128”, 2 entries
Codes read as this program: TXN10128.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.